The EPS beat and revenue ramp are notable for a micro-cap, but the absolute revenue base ($56K) remains negligible. Watch for REZENOPYTM launch execution and prescription growth for ArbliTM in Q2/Q3 2026 — the GPO contracts and sales force activation are the real catalysts. The $11M debt financing reduces near-term dilution risk but adds leverage.
Price Chart
Executive Summary
Scienture reported Q1 2026 revenue of $56K (up 449% YoY from $10K) and EPS of -$0.08, beating consensus of -$0.23 by 65.2%. Gross margin expanded to 95.6% from 6.6% on initial ArbliTM orders, but net loss widened to $3.4M from $3.1M. The company secured $11M in non-dilutive debt financing and highlighted GPO contracts covering 60% of the U.S. institutional market for REZENOPYTM, with a sales force launch scheduled for June 1, 2026.
Key Financial Metrics
Key Facts
- Revenue $56K vs $10K YoY (+449%), driven by ArbliTM wholesale orders
- EPS -$0.08 vs consensus -$0.23 (65.2% beat)
- Gross margin expanded to 95.6% from 6.6% YoY
- Net loss $3.4M vs $3.1M YoY, operating expenses flat at ~$3.56M
- Secured $11M non-dilutive debt financing to support commercialization and R&D
- GPO agreements for REZENOPYTM cover ~5,000 institutions / 60% of U.S. institutional market
- Sales force for REZENOPYTM scheduled to begin June 1, 2026
- Third USPTO patent granted for ArbliTM, extending exclusivity through 2041
Financial Impact
Revenue grew 449% YoY to $56K; gross profit surged 7,900% to $54K; net loss increased to $3.4M from $3.1M. $11M non-dilutive debt financing strengthens cash position from $3.5M at quarter-end.
Risk Factors
- Revenue base is tiny ($56K quarterly) — profitability remains distant despite 449% growth
- Net loss widened to $3.4M; cash burn rate implies ~6 months runway without additional financing
- REZENOPYTM launch is unproven — GPO contracts do not guarantee adoption or revenue
- Competition in naloxone nasal spray market (generic Narcan, RiVive) could limit pricing power
- Stock is micro-cap ($16M market cap) with low liquidity — price swings may be amplified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296641 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.77 | awaiting T+5 | — | $3.23 (+16.61%) |
Oct 19, 2026 8d ago | 8-K | $3.05 $3.23 | ▲ +5.90% | ▲ +5.82% | $3.23 (+5.90%) |
Oct 13, 2026 14d ago | Press Release | $3.24 $3.05 | ▲ +5.86% | ▲ +4.71% | $3.23 (+0.31%) |
Oct 7, 2026 20d ago | 8-K | $3.86 $3.38 | ▼ −12.44% | ▼ −12.16% | $3.23 (−16.32%) |
May 29, 2026 21w ago | 8-K | $0.3960 $0.3600 | ▼ −9.09% | ▼ −6.34% | $3.23 (+715.66%) |
May 22, 2026 22w ago | 8-K | $0.4000 $0.3910 | ▼ −2.25% | ▼ −3.46% | $3.23 (+707.50%) |
May 18, 2026 23w ago | Press Release | $0.3940 $0.4000 | ▲ +1.52% | ▼ −0.10% | $3.23 (+719.80%) |
May 5, 2026 25w ago | 8-K | $0.3910 $0.3980 | ▲ +1.79% | ▲ +0.66% | $3.23 (+726.09%) |
Apr 30, 2026 25w ago | 10-K/A | $0.4010 $0.4000 | ▲ +0.25% | ▲ +2.60% | $3.23 (−705.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers